This early-stage study will test a new vaccine concept using a genetically modified parasite to induce protection.
PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms— vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at www.path.org.
PATH's MALARIA VACCINE INITIATIVE (MVI) accelerates malaria vaccine development and catalyzes timely access in endemic countries, toward a world free from malaria. Standing at the intersection of malaria and immunization, MVI is part of PATH’s Center for Malaria Control and Elimination and PATH’s Center for Vaccine Innovation and Access. Learn more at www.malariavaccine.org or http://sites.path.org/cvia/.
Media enquiries
PATH/MVI |
Katy Lenard |
+1 301-280-5719 |
Washington/USA |
Press Radboudumc |
Pieter Lomans |
00-31-6-31970558 |
The Netherlands |
iMM Communication |
Ana de Barros |
(+351) 217 999 411 - ext: 47335 |
Portugal |